NEW YORK (GenomeWeb) – Canadian molecular diagnostics firm Qvella announced today it has raised $20 million in Series A financing.

The funding round was co-led by RA Capital Management and Whitecap Venture Partners, and included Hatteras Venture Partners and Sands Capital Ventures as syndicate partners.

"This latest round of funding provides us with the capital to support our ongoing research and development, and build out our team," Tino Alavie, president, CEO, and co-founder of Toronto-based Qvella, said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.

Nov
07
Sponsored by
Qiagen

This webinar will provide a first-hand look at how a leading pathology lab implemented a next-generation sequencing panel to capture comprehensive molecular tumor profiles.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.